Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2025-03-17 00:00:00 ET · period of report 2025-03-14 · accession 0000950170-25-039787 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-17 | 2025-03-14 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $7.20 | +6,074 | 306.2K | +2% | +$43.7K |
| D | 2025-03-17 | 2025-03-14 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $0.00 | +6,074 | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | M | A | 6,074 | $7.20 | 306,195 | D | — | — | |
| 2 | Derivative | Stock options (Right to buy) | 2025-03-14 | M | A | 6,074 | $0.00 | 0 | D | $7.20 · — to 2025-06-01 | 6,074 Common Stock | (F1) This option is fully vested. |